RIGL — Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc (RIGL) is a biotechnology company listed on NASDAQ. It is led by Raul R. Rodriguez, based in 611 Gateway Boulevard, South San Francisco, CA, United States, 94080, with about 162 employees. Rigel Pharmaceuticals, Inc., a biotechnology company, engages in discovering, developing, and providing therapies that enhance the lives of patients with hematologic disorders and cancer. The company's commercialized products include Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; Rezlidhia, a non-intensive monotherapy to treat adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test; and GAVRETO, a once daily, small molecule, oral, kinase inhibitor for the treatment of adult patients with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC), as well as to treat adult and pediatric patients twelve years of age and older with advanced or metastatic RET fusion-positive thyroid cancer. It also develops R289, an oral interleukin receptor-associated kinases 1 and 4 (IRAK1/4) inhibitor for the treatment of hematology-oncology, autoimmune, and inflammatory diseases, as well as to treat lower-risk myelodysplastic syndrome. In addition, the company has product candidates in clinical development with partners BerGenBio ASA, Eli Lilly and Company, and Daiichi Sankyo. It has strategic development collaboration with The University of Texas MD Anderson Cancer Center for the development of Olutasidenib in AML and other hematologic cancers with IDH1mutations, as well as with collaborative network for neuro-oncology clinical trials to evaluate Olutasidenib in combination with temozolomide in patients with high-grade glioma harboring an IDH1 mutation. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.

Latest reported RIGL revenue for 2025-09-30 was $69.5M. Net income was $99.0M. Revenue was down 31.7% from 2025-06-30 to 2025-09-30. RIGL currently screens at market cap $338.3M and trailing P/E 9.1.

Use this RIGL page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the RIGL quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the RIGL SEC filings page. Lician reads the product cache first so this HTML stays unique to Rigel Pharmaceuticals Inc even when a live quote feed is slow.